General Information |
| Summary |
This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial. |
| Description |
Solid tumor is a disease with high mortality rates. The aim of this trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial. |
| Clinical trials phase |
Not applicable |
| Start date (estimated) |
2024-02-01 |
| End date (estimated) |
2030-03-01 |
| Clinical feature |
| Label |
Solid Neoplasm |
| Link |
http://purl.obolibrary.org/obo/NCIT_C9292 |
| Description |
A benign or malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma). Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors. |
|
Administrative Information |
| NCT number |
NCT06245018 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06245018 |
| Source weblink |
https://clinicaltrials.gov/study/NCT06245018 |
| Public contact |
| Email |
xwgong@nuwacell.com |
| Public email |
xwgong@nuwacell.com |
| First name |
Xiaowen |
| Last name |
Gong |
| Phone |
+86 15221195602 |
| Country |
|
|
| Sponsors |
Nuwacell Biotechnologies Co., Ltd.
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
50 |
